Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Coagulation01:06

Coagulation

1.5K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.5K
Coagulation01:09

Coagulation

8.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

480
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
480
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hysterical disorders in patients with hematological diseases].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Localized AL amyloidosis].

Terapevticheskii arkhiv·2025
Same author

[Therapy of mental disorders in patients with hematological malignancies].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

[Adherence to treatment of hematological malignancies patients with anxiety and depression].

Terapevticheskii arkhiv·2023
Same author

[Visual acuity charts in the Russian Empire, the USSR and modern Russia].

Vestnik oftalmologii·2023
Same author

[Psychopharmacotherapy of mental disorders in hematological patients: security concerns].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023

Related Experiment Video

Updated: Apr 22, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

[Hypercoagulation syndrome in multiple myeloma].

E S Urnova, O S Pokrovskaia, M A Gracheva

    Terapevticheskii Arkhiv
    |October 16, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Over half of multiple myeloma patients exhibit hypercoagulability, increasing thrombosis risk. Prophylactic unfractionated heparin or aspirin effectively prevents thrombotic events in these high-risk individuals.

    More Related Videos

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    6.1K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Related Experiment Videos

    Last Updated: Apr 22, 2026

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    1.2K
    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    6.1K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Area of Science:

    • Hematology
    • Oncology
    • Thrombosis Research

    Context:

    • Multiple myeloma (MM) is associated with an increased risk of thromboembolic events.
    • Understanding the hemostatic alterations in MM is crucial for effective thromboprophylaxis.

    Purpose:

    • To investigate the prevalence and characteristics of blood clotting disorders in newly diagnosed multiple myeloma patients.
    • To assess the efficacy of preventive anticoagulant and antiplatelet therapies in this cohort.

    Summary:

    • A prospective study of 25 new-onset multiple myeloma patients revealed hypercoagulability in 68% and elevated D-dimer in 44%.
    • Advanced hemostatic techniques, including thrombodynamics, were employed to characterize clot formation and its relationship with disease parameters.
    • Prophylaxis with unfractionated heparin (500 U/hr infusion) or aspirin (100 mg/day) proved adequate in preventing thrombotic episodes.

    Impact:

    • This study highlights the significant prothrombotic tendency in multiple myeloma patients.
    • Findings support the use of specific anticoagulant and antiplatelet strategies for thromboprophylaxis in MM management.